Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hammerer

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Frontiers in Oncology|December 13, 2018
Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient OutcomesMarie C Hupe, Peter Hammerer, Miriam Ketz, et al.
BJU International|December 21, 2010
The influence of family history on prostate cancer risk: implications for clinical managementStephan Madersbacher, Antonio Alcaraz, Mark Emberton, et al.
European Urology|May 10, 2002
Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zoneAndreas Erbersdobler, Henning Fritz, Silvia Schnöger, et al.
The Journal of Urology|October 24, 2002
Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigenThomas Steuber, Paulina Nurmikko, Alexander Haese, et al.
Health and Quality of Life Outcomes|February 21, 2018
The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimationMartin H Umbehr, Lucas M Bachmann, Cedric Poyet, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 18, 2009
Frequency and gene expression profile of regulatory T cells in renal cell carcinomaAndreas Jeron, Susanne Pfoertner, Dunja Bruder, et al.
European Urology|May 20, 2004
Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosisMartin G Friedrich, Marieta I Toma, Susan Petri, et al.
International Urology and Nephrology|February 11, 2010
TVT vs. TOT: a comparison in terms of continence results, complications and quality of life after a median follow-up of 48 monthsVahudin Zugor, Apostolos P Labanaris, Mohammad-Reza Rezaei-Jafari, et al.
World Journal of Urology|September 28, 2014
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?Axel S Merseburger, Peter Hammerer, Francois Rozet, et al.
Urologia Internationalis|November 13, 2004
Extracorporeal shockwave lithotripsy compared with ureteroscopy for the removal of small distal ureteral stonesStefan Hautmann, Martin G Friedrich, Salvador Fernandez, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Frontiers in Oncology|December 13, 2018
Retrospective Analysis of Patients With Prostate Cancer Initiating GnRH Agonists/Antagonists Therapy Using a German Claims Database: Epidemiological and Patient OutcomesMarie C Hupe, Peter Hammerer, Miriam Ketz, et al.
BJU International|December 21, 2010
The influence of family history on prostate cancer risk: implications for clinical managementStephan Madersbacher, Antonio Alcaraz, Mark Emberton, et al.
European Urology|May 10, 2002
Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zoneAndreas Erbersdobler, Henning Fritz, Silvia Schnöger, et al.
The Journal of Urology|October 24, 2002
Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigenThomas Steuber, Paulina Nurmikko, Alexander Haese, et al.
Health and Quality of Life Outcomes|February 21, 2018
The German version of the Expanded Prostate Cancer Index Composite (EPIC): translation, validation and minimal important difference estimationMartin H Umbehr, Lucas M Bachmann, Cedric Poyet, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|July 18, 2009
Frequency and gene expression profile of regulatory T cells in renal cell carcinomaAndreas Jeron, Susanne Pfoertner, Dunja Bruder, et al.
European Urology|May 20, 2004
Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosisMartin G Friedrich, Marieta I Toma, Susan Petri, et al.
International Urology and Nephrology|February 11, 2010
TVT vs. TOT: a comparison in terms of continence results, complications and quality of life after a median follow-up of 48 monthsVahudin Zugor, Apostolos P Labanaris, Mohammad-Reza Rezaei-Jafari, et al.
World Journal of Urology|September 28, 2014
Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy?Axel S Merseburger, Peter Hammerer, Francois Rozet, et al.
Urologia Internationalis|November 13, 2004
Extracorporeal shockwave lithotripsy compared with ureteroscopy for the removal of small distal ureteral stonesStefan Hautmann, Martin G Friedrich, Salvador Fernandez, et al.
Pageof 6